BioScience Health Innovations Inc. reported a net loss of $229,907 for the three months ended March 31, 2026, compared with net income of $426,798 a year earlier. Revenue fell to $750,946 from $1,227,070, as the company shifted sales channels, brought in a new Amazon distributor, and saw a major co-brand order slip into the second quarter.
Operating costs climbed sharply, with general and administrative expenses rising to $625,809 and consulting fees to $89,694, partly tied to efforts to move from the OTC market to a senior exchange and to system upgrades. Despite the loss, cash increased to $1,145,005 and net working capital reached $1,549,089, helped by $437,067 from common stock issuance and related-party financing, including a new $460,402 note payable at 7%.
Management highlights a growing portfolio of patent-pending mitochondrial and mental-health products and believes current liquidity is sufficient for the next year. However, disclosure controls and internal control over financial reporting were deemed ineffective due to limited accounting resources, lack of segregation of duties, and absence of an independent board or audit committee.
BioScience Health Innovations Inc. reported a net loss of $229,907 for the three months ended March 31, 2026, compared with net income of $426,798 a year earlier. Revenue fell to $750,946 from $1,227,070, as the company shifted sales channels, brought in a new Amazon distributor, and saw a major co-brand order slip into the second quarter.
Operating costs climbed sharply, with general and administrative expenses rising to $625,809 and consulting fees to $89,694, partly tied to efforts to move from the OTC market to a senior exchange and to system upgrades. Despite the loss, cash increased to $1,145,005 and net working capital reached $1,549,089, helped by $437,067 from common stock issuance and related-party financing, including a new $460,402 note payable at 7%.
Management highlights a growing portfolio of patent-pending mitochondrial and mental-health products and believes current liquidity is sufficient for the next year. However, disclosure controls and internal control over financial reporting were deemed ineffective due to limited accounting resources, lack of segregation of duties, and absence of an independent board or audit committee.
Bioscience Health Innovations, Inc. reported a change to its Board of Directors. On April 1, 2026, director Justin Earl resigned, and the company stated his resignation was not due to any disagreement over operations, policies, or practices.
On the same day, the Board appointed Daniel Schmidt, the company’s long-time Chief Technology Officer, to fill the vacant board seat, effective immediately. Schmidt brings 26 years of experience developing and commercializing therapeutic medical devices and treatments aimed at improving quality of life.
Bioscience Health Innovations, Inc. reported a change to its Board of Directors. On April 1, 2026, director Justin Earl resigned, and the company stated his resignation was not due to any disagreement over operations, policies, or practices.
On the same day, the Board appointed Daniel Schmidt, the company’s long-time Chief Technology Officer, to fill the vacant board seat, effective immediately. Schmidt brings 26 years of experience developing and commercializing therapeutic medical devices and treatments aimed at improving quality of life.
BioScience Health Innovations Inc. reported strong growth for the year ended December 31, 2025. Revenue rose to $5,688,717, a 208% increase from 2024, while net income increased to $642,090, expanding net margin from 4.7% to 11.3%. The company sells health and wellness products via subsidiary Best 365 Labs and leverages its patent‑pending MODS Max delivery system for supplements and peptide-based formulations.
Total assets reached $1,707,181 with cash of $661,925 and working capital of $1,328,807, and operations generated positive operating cash flow. BioScience is pursuing a $1.5 million Regulation A raise followed by an additional planned $5–7.5 million capital raise tied to a major exchange uplist, potentially supported by a reverse stock split. Management highlights testosterone optimization, NAD+ and cellular health, and platform licensing of MODS Max as its three core growth drivers.
The company remains a microcap OTC Pink “penny stock” with thin trading, material weaknesses in internal controls, and significant historical reliance on related-party inventory sourcing. It is also executing a separation from related-party Ageless Holdings and expanding infrastructure, including new facilities, an Oracle NetSuite ERP implementation, and planned AI tools to support scaling.
BioScience Health Innovations Inc. reported strong growth for the year ended December 31, 2025. Revenue rose to $5,688,717, a 208% increase from 2024, while net income increased to $642,090, expanding net margin from 4.7% to 11.3%. The company sells health and wellness products via subsidiary Best 365 Labs and leverages its patent‑pending MODS Max delivery system for supplements and peptide-based formulations.
Total assets reached $1,707,181 with cash of $661,925 and working capital of $1,328,807, and operations generated positive operating cash flow. BioScience is pursuing a $1.5 million Regulation A raise followed by an additional planned $5–7.5 million capital raise tied to a major exchange uplist, potentially supported by a reverse stock split. Management highlights testosterone optimization, NAD+ and cellular health, and platform licensing of MODS Max as its three core growth drivers.
The company remains a microcap OTC Pink “penny stock” with thin trading, material weaknesses in internal controls, and significant historical reliance on related-party inventory sourcing. It is also executing a separation from related-party Ageless Holdings and expanding infrastructure, including new facilities, an Oracle NetSuite ERP implementation, and planned AI tools to support scaling.
BioScience Health Innovations (BHIC) filed its quarterly report for the period ended September 30, 2025. The company posted strong year-to-date results, with revenue of $4,115,960 and net income of $875,720, compared with $1,234,744 and $77,043 a year earlier. In Q3, revenue was $1,131,427 and the company recorded a small net loss of $8,782 as operating expenses rose with growth.
Cash was $1,139,423, inventory increased to $757,500, and total assets reached $2,067,100. Current liabilities were $356,140, including $228,298 due to related parties. Operating cash flow was positive at $272,874. The company expanded authorized common stock to 250,000,000 and executed a 1‑for‑4 reverse split; 10,979,055 common shares were outstanding as of October 24, 2025. There are 140,000 Series A preferred shares outstanding, each convertible into three common shares subject to a 4.99% beneficial ownership limit.
Management disclosed material weaknesses in internal controls and noted substantial doubt about the company’s ability to continue as a going concern due to historical losses and reliance on related-party advances, despite improved year-to-date profitability.
BioScience Health Innovations (BHIC) filed its quarterly report for the period ended September 30, 2025. The company posted strong year-to-date results, with revenue of $4,115,960 and net income of $875,720, compared with $1,234,744 and $77,043 a year earlier. In Q3, revenue was $1,131,427 and the company recorded a small net loss of $8,782 as operating expenses rose with growth.
Cash was $1,139,423, inventory increased to $757,500, and total assets reached $2,067,100. Current liabilities were $356,140, including $228,298 due to related parties. Operating cash flow was positive at $272,874. The company expanded authorized common stock to 250,000,000 and executed a 1‑for‑4 reverse split; 10,979,055 common shares were outstanding as of October 24, 2025. There are 140,000 Series A preferred shares outstanding, each convertible into three common shares subject to a 4.99% beneficial ownership limit.
Management disclosed material weaknesses in internal controls and noted substantial doubt about the company’s ability to continue as a going concern due to historical losses and reliance on related-party advances, despite improved year-to-date profitability.
BioScience Health Innovations, Inc. effected a reverse stock split, consolidating every 4 shares of common stock into 1 share, effective September 10, 2025. The Board approved the action under Nevada law, and a majority of shares entitled to vote approved it by written consent.
The company states the reverse split does not affect stockholder rights, and no other amendments were made to the certificate of incorporation. A certificate of amendment was filed with the Nevada Secretary of State.
BioScience Health Innovations, Inc. effected a reverse stock split, consolidating every 4 shares of common stock into 1 share, effective September 10, 2025. The Board approved the action under Nevada law, and a majority of shares entitled to vote approved it by written consent.
The company states the reverse split does not affect stockholder rights, and no other amendments were made to the certificate of incorporation. A certificate of amendment was filed with the Nevada Secretary of State.